Melittin

The 26-residue principal toxic peptide of European honey bee venom, a cationic amphipathic helix that lyses cell membranes, with a large preclinical anticancer and antimicrobial literature, no FDA-approved product, and marked hemolytic toxicity.

Also referenced as: Api m 4, MEL, MLT

Also appears in: Immune

COA Public product evidence No certificate records are bound to a tracked Melittin product page A record counts here only when a vendor publishes a certificate against one of its own tracked Melittin product pages. Other certificates naming this compound may still exist — search the wider certificate database. →

---

What is Melittin?

Melittin is a 26-amino-acid peptide and the principal toxic component of the venom of the European honey bee, Apis mellifera (Raghuraman and Chattopadhyay, Bioscience Reports, 2007). Its sequence is Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln, written GIGAVLKVLTTGLPALISWIKRKRQQ. The venom gland makes it as a 70-residue precursor: a 21-residue signal sequence, a 22-residue acidic propeptide removed by a dipeptidylpeptidase, then the mature chain at positions 44 to 69, whose C-terminal glutamine is amidated and whose N-terminal glycine is partly formylated. The opening stretch is hydrophobic apart from a single lysine, the only proline sits at position 14, and the final residues carry the basic cluster Lys-Arg-Lys-Arg, which together give the molecule its amphipathic, strongly cationic character. In concentrated salt solutions and in two crystal forms the peptide is a bent amphipathic helical rod that assembles into a tetramer, with four helices turning their hydrophobic faces toward the center (Terwilliger et al., Biophysical Journal, 1982).

Melittin also carries the honey bee venom allergen designation Api m 4, and the UniProt reference record preserves the earlier designations Api m 3 and Api m III together with the short forms MEL and MLT (Paull et al., Journal of Allergy and Clinical Immunology, 1977). It is one of the most studied membrane-active peptides in biophysics and serves as a standard model compound for peptide-lipid interaction work, alongside host-defense peptides such as LL-37. Drugs@FDA lists no application for melittin, ClinicalTrials.gov lists no interventional study with melittin itself as an intervention, and the human data that exist come from whole bee venom given as bee-venom therapy rather than from the isolated peptide.

How it works

• Amphipathic helix that binds and reorganizes lipid bilayers. Melittin adsorbs strongly to the bilayer interface, inserts its hydrophobic face, and changes the local packing and surface order of both artificial and biological membranes; this interfacial activity, rather than a receptor, is the basis of its action (Raghuraman and Chattopadhyay, Bioscience Reports, 2007; Zorilă et al., Toxins, 2020).
• Two distinct pore states set by concentration. At nanomolar concentrations melittin induces transient pores that conduct atomic ions but do not allow leakage of glucose or larger molecules; at micromolar concentrations it induces stable pores that leak molecules up to tens of kilodaltons, the range corresponding to its antimicrobial activity. Peptide bound to one side of a vesicle translocates and redistributes to both sides before stable pores appear, stable pores form only above a critical peptide-to-lipid ratio, and anomalous X-ray diffraction showed that the pore is lipidic, formed where two interfaces merge through a hole (Lee et al., Proceedings of the National Academy of Sciences, 2013).
• Reinforcement of venom phospholipase A2. Melittin enhances the activity of bee venom phospholipase A2 on membrane substrates, an enhancement also produced by other basic lytic agents such as polymyxin B and the direct lytic factor of cobra venom, so the two major venom components act on the same membrane in a mutually reinforcing way (Mollay and Kreil, FEBS Letters, 1974).
• Receptor-adjacent effects in tumor cells. Beyond frank lysis, melittin interferes with phosphorylation of EGFR and HER2 in the plasma membrane of breast carcinoma cells, and mutational work localized membrane interaction and anticancer activity to the positively charged C-terminal sequence (Duffy et al., npj Precision Oncology, 2020). Because the same physical chemistry drives both lysis and selectivity, selectivity has to be engineered rather than assumed.

Research status

Oncology is preclinical and delivery-limited. The most cited in vivo result used melittin incorporated into the outer lipid monolayer of a perfluorocarbon nanoparticle: the nanocarrier accumulated melittin in murine tumors, reduced tumor growth without apparent signs of toxicity, delivered the peptide to endothelial and cancer cells through hemifusion rather than surface disruption, triggered apoptosis, and caused regression of precancerous dysplastic lesions (Soman et al., Journal of Clinical Investigation, 2009). Duffy et al. reported that honeybee venom and melittin potently induced cell death in triple-negative and HER2-enriched breast cancer lines, that engineering an RGD motif further enhanced targeting of malignant cells with minimal toxicity to normal cells, and that melittin enhanced the effect of docetaxel on breast tumor growth in an allograft model (npj Precision Oncology, 2020). Work since then has stayed at the same stage. A systematic review of bee venom-derived apamin and melittin conjugates in cancer found only laboratory and animal studies (Laurindo et al., Pharmacological Research, 2024), and 2026 syntheses continue to frame the field as mechanism mapping plus formulation chemistry rather than clinical development (Tan et al., Current Opinion in Pharmacology, 2026; Xiong et al., International Journal of Nanomedicine, 2026). Oncolytic peptides that did reach trials, such as LTX-315, are separate molecules.

Antimicrobial activity is reproducible in vitro and inconsistent in animals. A 2026 review restricted to in vivo studies concluded that melittin can reduce microbial burdens in selected experimental infection models and can modulate inflammatory responses, but that the magnitude and nature of those effects vary with the pathogen, infection model, host context, administration route, dose and formulation, and that its therapeutic window, pharmacokinetics, biodistribution, long-term safety and immunogenicity all remain to be defined (Memariani et al., World Journal of Microbiology and Biotechnology, 2026). An antiviral proof of concept found that free melittin at doses below 2 µM was not cytotoxic to reporter cells and reduced infectivity of both CXCR4-tropic and CCR5-tropic HIV-1, yet lowered vaginal epithelial cell viability at every dose tested, while a nanoparticle form left those cells unaffected and inhibited the two strains with 50% inhibitory concentrations of 2.4 and 3.6 µM (Hood et al., Antiviral Therapy, 2013). That dissociation between free and formulated peptide recurs across the literature.

Chemistry aimed at the toxicity problem. Analog and conjugate work is the active area. Terminal PEGylation modulates membrane-disruptive activity (Chen et al., Bioconjugate Chemistry, 2025), assembly with a Pluronic block copolymer preserved anticancer selectivity while attenuating hemolytic activity (Król et al., Frontiers in Oncology, 2026), polyphenol-mediated peptide assembly neutralizes the interfacial affinity that drives membrane binding (Han et al., ACS Applied Materials and Interfaces, 2025), and a nanocarrier review catalogs the delivery platforms tried so far along with the remaining translational obstacles (Xiong et al., International Journal of Nanomedicine, 2026). Reviews of rheumatoid arthritis and neuroprotection applications likewise report animal and cell data only (Huang et al., Toxicon, 2025; Kadyan and Singh, Molecular Neurobiology, 2025).

Human exposure has been studied as whole venom, not as melittin. A randomized double-blind trial registered as NCT01341431 assigned 40 patients with Parkinson disease at Hoehn and Yahr stages 1.5 to 3 to monthly subcutaneous bee venom injections of 100 µg or equivalent volumes of saline, 20 per group. After 11 months, motor scores in the off condition did not improve, the course of those scores and dopamine transporter imaging did not differ between groups, four patients were excluded after positive skin tests, and no systemic allergic reaction was recorded (Hartmann et al., PLoS One, 2016). A systematic review of randomized trials of bee venom in indications other than cancer included 12 trials, three in Parkinson disease, four in arthralgia, four in musculoskeletal disorders and one in polycystic ovary syndrome; six reported adverse events, and skin reactions such as pruritus and swelling were the most common (Jang and Kim, Toxins, 2020). The furthest-advanced US program used a purified honeybee toxin preparation rather than melittin: a phase 3 trial of that preparation against a histamine comparator in 363 adults with refractory knee osteoarthritis reached primary completion in November 2016 and carries no posted results (NCT01112722), and a planned 468-participant phase 3 trial of the same preparation in multiple sclerosis has been listed with unknown status since its October 2018 update (NCT03710655). As of November 2026 no FDA-approved product contains melittin and no registered interventional trial of the isolated peptide exists.

Common dosage forms

• No approved presentation. No vial, ampoule, pen, tablet, spray or topical product containing melittin as an active ingredient holds FDA approval.
• Laboratory material. Research-grade melittin is supplied as a lyophilized powder in milligram quantities for in vitro and animal work, handled by laboratory personnel rather than by clinicians.
• Experimental formulations. Perfluorocarbon nanoparticles, polymeric and lipid carriers, hydrogels, PEGylated conjugates and hybrid peptides exist only as preparations made for cell and animal studies.

Key considerations

• Regulatory status. The Research Market status reflects the absence of any FDA-approved product containing melittin as an active ingredient. Drugs@FDA lists no application for melittin, and the FDA-licensed honey bee venom products are allergenic extracts of whole venom used for diagnosis and immunotherapy of insect-sting allergy, and the unapproved topical products listing bee venom in the national drug labeling database are listings rather than approvals.
• Hemolytic toxicity is the defining limitation. Melittin lyses red blood cells and healthy nucleated cells through the same interfacial mechanism that kills bacteria and tumor cells, with no inherent selectivity for diseased membranes (Richardson and Van Lehn, Journal of Physical Chemistry B, 2025; Doltchinkova et al., Membranes, 2025). Every therapeutic proposal in the literature depends on a carrier or an analog to blunt that activity.
• Anaphylaxis risk is documented for venom exposure. Melittin is a recognized bee venom allergen, and a systematic overview of pharmacovigilance databases for apitherapeutic products identified anaphylaxis and fatalities following therapeutic use of bee venom, with allergic responses the most prevalent adverse event and atopic individuals most affected (Rocha Filho et al., Archives of Toxicology, 2026).
• Animal and in vitro results do not transfer. The oncology and anti-infective findings come from cell lines, mouse allografts and selected infection models, usually with a delivery vehicle that changes the pharmacology of the free peptide. No pharmacokinetic, dose-response or safety dataset for melittin in humans has been published.
• Naming. Melittin is designated Api m 4 as a honey bee venom allergen and is abbreviated MEL or MLT. It is not the same thing as whole bee venom, also called apitoxin, which additionally contains phospholipase A2, hyaluronidase, apamin and mast cell degranulating peptide, so the clinical evidence gathered for whole venom preparations establishes nothing about the isolated peptide.